Holen Sie sich die Stockscreener-App
20.82
0.77%
-0.035
Schlusskurs vom Vortag:
$20.85
Offen:
$20.93
24-Stunden-Volumen:
129.76K
Relative Volume:
0.01
Marktkapitalisierung:
$1.14B
Einnahmen:
$29.71M
Nettoeinkommen (Verlust:
$-69.15M
KGV:
-21.46
EPS:
-0.97
Netto-Cashflow:
$-52.28M
1W Leistung:
+5.40%
1M Leistung:
+5.72%
6M Leistung:
+55,518%
1J Leistung:
+55,518%
1-Tages-Spanne:
$20.38
$21.63
1-Wochen-Bereich:
$19.03
$21.63
52-Wochen-Spanne:
$16.80
$29.16
Aktis Oncology Inc Stock (AKTS) Company Profile
Firmenname
Aktis Oncology Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare AKTS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
20.59 | 1.15B | 29.71M | -69.15M | -52.28M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.69 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.88 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
726.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.44 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
290.22 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-03 | Eingeleitet | BofA Securities | Buy |
| 2026-02-03 | Eingeleitet | JP Morgan | Overweight |
| 2026-02-03 | Eingeleitet | Leerink Partners | Outperform |
| 2026-02-03 | Eingeleitet | TD Cowen | Buy |
| 2024-01-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-09-06 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-01-24 | Eingeleitet | B. Riley Securities | Buy |
| 2021-02-02 | Bestätigt | Craig Hallum | Buy |
| 2021-01-15 | Bestätigt | Craig Hallum | Buy |
| 2019-09-18 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-07-10 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2019-05-13 | Bestätigt | Craig Hallum | Buy |
| 2019-02-05 | Bestätigt | Craig Hallum | Buy |
| 2019-02-05 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-12-18 | Eingeleitet | Craig Hallum | Buy |
| 2018-11-30 | Eingeleitet | Lake Street | Buy |
| 2018-06-22 | Eingeleitet | Loop Capital | Buy |
| 2018-02-09 | Eingeleitet | Drexel Hamilton | Buy |
Alle ansehen
Aktis Oncology Inc Aktie (AKTS) Neueste Nachrichten
Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors - TipRanks
AKTS: New miniprotein radiopharmaceuticals target broad solid tumor markets, advancing in clinic - TradingView
AKTS: Lead radiopharmaceutical assets advance toward major milestones in a rapidly expanding market - TradingView
BUDA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AKTS Technical Analysis & Stock Price Forecast - Intellectia AI
IPO Tracker 2026: Generate Clocks Largest IPO Since 2024 With $400M Raise - BioSpace
Assessing Aktis Oncology (AKTS) Valuation As Shares Show Short Term Momentum Rebound - Yahoo Finance
Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target - TipRanks
Aktis Oncology to Present at Upcoming March Investor Conferences - The Manila Times
Aktis Oncology (AKTS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $AKTS - MarketBeat
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate - Bitget
Aktis Oncology receives U.S. FDA fast track designation for Aky-1189 - marketscreener.com
Aktis Oncology's AKY-1189 Wins FDA Fast Track Designation - Nasdaq
Flagship-Backed Generate Bio Seeks $425 Million in US IPO - Bloomberg.com
Flagship-Backed Generate Biomedicines Seeks $425 Million in IPO - Bloomberg.com
Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO - Reuters
Ken Herrmann Net Worth (2026) - GuruFocus
US Index IPO ForecastMar26: 8 Additions Including Medline & BETA Technologies - Smartkarma
Huge insider buying now at this insurance giant and 2 biotechs - MSN
2026 kicks off with $10.8B January financing haul - BioWorld MedTech
Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut - WTVB
Eikon’s $381M raise represents largest biopharma IPO in two years - BioWorld MedTech
Eikon Therapeutics raises $381M in IPO - Axios
Merck Veteran-Led Eikon Therapeutics Raises $381 Million in IPO - Bloomberg.com
Biopharma Co.'s Down-Round IPO May Signal More To Come - Law360
This GCI Liberty Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday - Benzinga
Aktis Oncology: Differentiated Miniprotein Radiopharma Platform Underpins Buy Rating and Multi-Billion Dollar Sales Potential - TipRanks
Merck veteran Perlmutter-led Eikon Therapeutics eyes $908 million valuation in IPO - Reuters
Eikon ?Therapeutics targets $908 million valuation in US IPO - marketscreener.com
Eikon sets $274M goal for upcoming stock market debut - Fierce Biotech
Carvina Capital: Strong Demand Lifts Aktis IPO - Barchart.com
Aktis Oncology prices IPO at $18 per share - MSN
Why Revolution Medicines Stock Surged by 11% Today - AOL.com
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs - AOL.com
Investors Scoop Up Shares in Key Insurance and Biotech Companies - finance.coin-turk.com
‘No reasons to own’: Software stocks sink on fear of new AI tool - The Japan Times
Assessing Aktis Oncology (AKTS) Valuation After IPO, NASDAQ Inclusion And Heavy Insider And Institutional Buying - Yahoo Finance
AKTS SEC FilingsAKTIS ONCOLOGY INC 10-K, 10-Q, 8-K Forms - Stock Titan
United StatesGoodwin Advises Aktis Oncology In Closing Of $365.4 Million Upsized Initial Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares - Mondaq
Wednesday Insider Activity: Mitsui’s $55.6M Berkley Buy Leads the Pack - Investing.com Nigeria
Wednesday Insider Activity: Mitsui’s $55.6M Berkley Buy Leads the Pack By Investing.com - Investing.com South Africa
Biotech Venture Limped Through 2025. A Brighter 2026 Beckons. - The Wall Street Journal
Insiders Make Bold Move as Key Players Double Down on Aktis Oncology - TipRanks
Aktis Oncology director Foley buys $4.19 million in shares By Investing.com - Investing.com India
Aktis Oncology: Mpm funds buy shares worth $20m By Investing.com - Investing.com Nigeria
Aktis Oncology: Mpm funds buy shares worth $20m - Investing.com
Aktis Oncology (AKTS) sees $20 million purchase by 10% owner - Investing.com South Africa
Finanzdaten der Aktis Oncology Inc-Aktie (AKTS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aktis Oncology Inc-Aktie (AKTS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Jan 12 '26 |
Buy |
18.00 |
1,112,777 |
20,029,986 |
10,260,064 |
| GADICKE ANSBERT | 10% Owner |
Jan 12 '26 |
Buy |
18.00 |
1,112,777 |
20,029,986 |
10,260,064 |
| EcoR1 Capital, LLC | Director |
Jan 12 '26 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
4,348,658 |
| Vida Ventures II, LLC | 10% Owner |
Jan 12 '26 |
Buy |
18.00 |
835,000 |
15,030,000 |
5,671,825 |
| Kim Helen Susan | Director |
Jan 12 '26 |
Buy |
18.00 |
835,000 |
15,030,000 |
5,671,825 |
3.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):